Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

benzinga.com/news/health-care/25/07/46401053/amylyxs-avexitide-patients-weight-loss-surgery

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025).
The drug targets post-bariatric…

This story appeared on benzinga.com, 2025-07-14 18:15:11.
The Entire Business World on a Single Page. Free to Use →